• Save
Wyeth Remake Analyst Meeting 10-05-06 slides 4-8
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Wyeth Remake Analyst Meeting 10-05-06 slides 4-8

on

  • 1,484 views

 

Statistics

Views

Total Views
1,484
Views on SlideShare
1,477
Embed Views
7

Actions

Likes
0
Downloads
0
Comments
0

1 Embed 7

http://i3mm.blogspot.com 7

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Wyeth Remake Analyst Meeting 10-05-06 slides 4-8 Presentation Transcript

  • 1. Remake of October 5, 2006 Wyeth Analyst Meeting slides 4-8 http://phx.corporate-ir.net/phoenix.zhtml?c=78193&p=irol-presentations
  • 2. Agenda 4 Break New Products U. Wiinberg Enbrel® & Prevnar® E.A. Emini, Ph.D. Prevnar 13 R. Essner Introduction J. Victoria Welcome Tygacil® J.S. Camardo, M.D. Torisel™ Lybrel™ G. Constantine, M.D. Aprela™ / Viviant™ J.S. Camardo, M.D. Methylnaltrexone R.M. Poole, M.D., FACP Bifeprunox J.M. Mahady Pristiq™ B. Poussot Conclusion and Q&A Key Registration Submissions R.R. Ruffolo, Jr., Ph.D. Mid-Pipeline Review
  • 3. Introduction 5 Robert Essner Chairman and Chief Executive Officer, Wyeth
  • 4. Wyeth Past Business Performance 7% 3% 9% 10% 8% Revenue Growth (in billions) 6 WHI
  • 5. Wyeth Past Business Performance 11% 15% 2% 10% 7% EPS* Growth 7 WHI July Guidance * Before Certain Significant items
  • 6. EPS Continues to Grow in 2006 12% 11% 15% 2% 10% 7% EPS* Growth 8 WHI +** July Guidance * Before Certain Significant items ** When Adjusted for Stock Option Expensing in 2005